Teladoc and LifeMD announce LillyDirect self-pay Zepbound integrations

On March 6, 2025, two major telehealth companies, Teladoc Health and LifeMD, said they had signed deals to connect their patients to Gifthealth, the pharmacy partner behind Eli Lilly's LillyDirect platform, so people can buy branded Zepbound (tirzepatide) instead of compounded versions of the drug ^[1][2].

Under the Teladoc deal, members enrolled in its Comprehensive Weight Care Program who lack insurance coverage for GLP-1 drugs can get single-use Zepbound vials shipped to their homes if a Teladoc provider prescribes the drug for an FDA-approved use. Teladoc says its own clinical teams will track the process from dispensing through shipping, delivery, and refills ^[1]. Kelly Bliss, president of U.S. Group Health at Teladoc Health, said the move helps members "afford transformative FDA-approved treatments while avoiding the potential risks of compounded medications recently offered by others" ^[1]. The company said it does not sell compounded GLP-1 drugs itself ^[2].

LifeMD's arrangement works the same way, giving self-pay members access to branded Zepbound vials at what the company called Lilly's newly reduced self-pay price ^[2]. Unlike Teladoc, LifeMD has been offering compounded GLP-1 drugs and said it is prepared to adjust if rules change further ^[2]. Neither company's statement includes the specific dollar price patients will pay; Lilly's press materials point customers to pricing posted on LillyDirect's own site ^[1].

The timing lines up with legal and regulatory pressure on compounded copies. A federal judge on March 5, 2025, denied a request for an injunction that would have let compounding pharmacies keep making copies of Zepbound ^[2]. The FDA had also already declared that shortages of Zepbound and of Novo Nordisk's Wegovy and Ozempic (semaglutide) were resolved, a status change that limits the legal basis for mass compounding of copies ^[2]. Citi analyst Daniel Grosslight said the Teladoc and LifeMD deals point to more agreements of this kind as bulk compounding is likely to be significantly curtailed going forward ^[2]. Telehealth company Ro had already set up a similar direct link to LillyDirect in December 2024, offering single-dose Zepbound vials ^[2].

Why it matters for patients

For people who have relied on lower-cost compounded tirzepatide because they lack insurance coverage, these deals create a route to get the FDA-approved brand-name drug through telehealth services many already use, at a self-pay price set by Lilly ^[1][2]. Teladoc frames this as a way to reduce exposure to compounded products, which are not FDA-approved for safety and effectiveness in the same way ^[1]. At the same time, patients using LifeMD may still have access to compounded options for now, since that company said it will only change course as legal restrictions demand ^[2]. The exact price difference between branded self-pay Zepbound and compounded alternatives is not detailed in these announcements, so patients comparing costs would need to check current pricing directly.

What happens next

The legal fight over compounded copies of Zepbound was still active as of March 5, 2025, when a judge declined to block further restrictions on compounding pharmacies ^[2]. With Zepbound, Wegovy, and Ozempic no longer listed as being in shortage by the FDA, the sources say compounding pharmacies face a shrinking legal window to keep selling copies ^[2]. It is not yet known from these sources exactly when remaining compounded supplies will run out or whether more telehealth companies will announce similar branded-drug deals, though analysts expect additional agreements ^[2].